#37 How many lives would be changed with effective prevention of thromboembolic events? John Glasspool, CEO of Anthos Therapeutics

An interview with John Glasspool, CEO of Anthos Therapeutics. Did you know that VTE is the 2nd leading cause of death in cancer patients after the cancer itself? Did you know that many patients choose not to us the current standard of care to blood clotting due to excessive bleeding? Anthos Therapeutics is addressing this major unmet medical need in thromboembolic events with their lead candidate abelacimab. Abelacimab is an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI.https://anthostherapeutics.com/https://thebiotechiqpodcast.com/Support the showCheck me out on LinkedIn https://www.linkedin.com/in/ammonr/